Business Description
Kiora Pharmaceuticals Inc
NAICS : 325413
SIC : 2835
ISIN : US30233M1071
Description
Kiora Pharmaceuticals Inc is a clinical-stage biotechnology company developing and commercializing products for the treatment of orphan retinal diseases. As part of its development, KIO-301 is being studied for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration. KIO-104 is being developed for the treatment of posterior non-infectious uveitis. It is a next-generation, non-steroidal, immuno-modulatory, and small-molecule inhibitor of dihydroorotate dehydrogenase.
Financial Strength
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 332.72 | |||||
| Equity-to-Asset | 0.82 | |||||
| Debt-to-EBITDA | 0.04 | |||||
| Interest Coverage | 519 | |||||
| Piotroski F-Score | 6/9 | |||||
| Altman Z-Score | -1.76 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | 64.9 | |||||
| 3-Year EPS without NRI Growth Rate | 68.9 | |||||
| 3-Year FCF Growth Rate | 68.6 | |||||
| 3-Year Book Growth Rate | -77.5 |
Momentum Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 44.56 | |||||
| 9-Day RSI | 49.43 | |||||
| 14-Day RSI | 48.9 | |||||
| 6-1 Month Momentum % | 0.9 | |||||
| 12-1 Month Momentum % | -76.69 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 21.02 | |||||
| Quick Ratio | 21.02 | |||||
| Cash Ratio | 19.63 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -281.4 | |||||
| Shareholder Yield % | -137.4 |
Profitability Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Operating Margin % | 38.93 | |||||
| Net Margin % | 17.54 | |||||
| FCF Margin % | 44.35 | |||||
| ROE % | 19.25 | |||||
| ROA % | 12.94 | |||||
| ROIC % | 60.74 | |||||
| ROC (Joel Greenblatt) % | 2456.86 | |||||
| ROCE % | 12.64 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Forward PE Ratio | 2.8 | |||||
| Price-to-Owner-Earnings | 7.69 | |||||
| PS Ratio | 1.19 | |||||
| PB Ratio | 0.41 | |||||
| Price-to-Tangible-Book | 0.55 | |||||
| EV-to-EBIT | -6.72 | |||||
| EV-to-EBITDA | -6.6 | |||||
| EV-to-Revenue | -1.05 | |||||
| EV-to-Forward-Revenue | 0.66 | |||||
| EV-to-FCF | -2.36 | |||||
| Price-to-Net-Current-Asset-Value | 0.55 | |||||
| Price-to-Net-Cash | 0.61 | |||||
| Earnings Yield (Greenblatt) % | -14.88 | |||||
| FCF Yield % | 49.8 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Kiora Pharmaceuticals Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 14.72 | ||
| EPS (TTM) (€) | -1.483 | ||
| Beta | -0.04 | ||
| Volatility % | 93.18 | ||
| 14-Day RSI | 48.9 | ||
| 14-Day ATR (€) | 0.017573 | ||
| 20-Day SMA (€) | 0.442975 | ||
| 12-1 Month Momentum % | -76.69 | ||
| 52-Week Range (€) | 0.4 - 1.89 | ||
| Shares Outstanding (Mil) | 26.26 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 6 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Kiora Pharmaceuticals Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Kiora Pharmaceuticals Inc Stock Events
| Event | Date | Price(€) | ||
|---|---|---|---|---|
| No Event Data | ||||
Kiora Pharmaceuticals Inc Frequently Asked Questions
What is Kiora Pharmaceuticals Inc(FRA:7EY0)'s stock price today?
The current price of FRA:7EY0 is €0.45. The 52 week high of FRA:7EY0 is €1.89 and 52 week low is €0.40.
When is next earnings date of Kiora Pharmaceuticals Inc(FRA:7EY0)?
The next earnings date of Kiora Pharmaceuticals Inc(FRA:7EY0) is .
Does Kiora Pharmaceuticals Inc(FRA:7EY0) pay dividends? If so, how much?
Kiora Pharmaceuticals Inc(FRA:7EY0) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers